Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Whitehawk Therapeutics, Inc. reported revenue of $7M, down 72.5% year over year. Operating margin was -1601.1% and net margin -288.3%, on a free-cash-flow margin of -1371.4% with capital expenditure at 7.7% of revenue. Every figure is computed directly from WHWK's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $7M | -1601.1% | -288.3% |
| FY2024 | $26M | -259.6% | -245.1% |
| FY2023 | $24M | -295.4% | -270.0% |
| FY2022 | $15M | -411.9% | -397.7% |
| FY2021 | $14M | -794.4% | -786.4% |
How does WHWK compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.